Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema

• Diana V. Do, Quan D. Nguyen, +8 authors Peter Anthony Campochiaro
• The British journal of ophthalmology
• 2009

AIM The aim of the study was to assess the safety and bioactivity of a single intravitreal injection of vascular endothelial growth factor (VEGF) Trap-Eye in subjects with diabetic macular oedema… (More)

The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.

• Jeffrey S. Heier, David S. Boyer, +9 authors David M. Brown
• Ophthalmology
• 2011

OBJECTIVE To evaluate anatomic outcomes and vision, injection frequency, and safety during the as-needed (PRN) treatment phase of a study evaluating a 12-week fixed dosing period followed by PRN… (More)

A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.

• Quan D. Nguyen, Syed Mahmood Ali Shah, +15 authors Peter Anthony Campochiaro
• Ophthalmology
• 2009

PURPOSE To determine the safety, tolerability, maximum tolerated dose, and bioactivity of an intravitreal injection of vascular endothelial growth factor (VEGF) Trap-Eye, a fusion protein of binding… (More)

Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration.

• David M. Brown, Jeffrey S. Heier, +9 authors Quan D. Nguyen
• Ophthalmology
• 2011

OBJECTIVE To evaluate the biologic effects and safety of vascular endothelial growth factor (VEGF) Trap-Eye during a 12-week fixed-dosing period in patients with neovascular (wet) age-related macular… (More)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%

• Jack V. Greiner, Kimberly Edwards-Swanson, Avner Ingerman
• Clinical ophthalmology
• 2011

PURPOSE To evaluate the effectiveness of alcaftadine 0.05%, 0.1%, and 0.25% ophthalmic solutions in treating the signs and symptoms of allergic conjunctivitis when compared with olopatadine… (More)

Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial.

• Emily Y. Chew, Traci E. Clemons, +7 authors Alan C. Bird
• American journal of ophthalmology
• 2015

PURPOSE To evaluate the safety and tolerability of intraocular delivery of ciliary neurotrophic factor (CNTF) using an encapsulated cell implant for the treatment of macular telangiectasia type 2. … (More)

Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration.

• Quan D. Nguyen, Peter Anthony Campochiaro, +14 authors Jesse Cedarbaum
• Journal of ocular pharmacology and therapeutics…
• 2012

PURPOSE To determine bioactivity and duration of effect of intravitreal aflibercept injection (also known as vascular endothelial growth factor Trap-Eye) for neovascular age-related macular… (More)

The Effectiveness of Alcaftadine Ophthalmic Solution as Evaluated in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis at 15 Minutes and 16 Hours After Instillation

• Jack V. Greiner, Avner Ingerman
• 2011

• ‹
• 1
• ›